The PDUFA date is May 1, 2027, with an AdCom likely in early 2027. The confirmatory trial screening start by end of 2026 is a near-term catalyst. Monitor AdCom outcome and any safety/efficacy signals from the ongoing Phase I/II data. The stock's 3.1% normal daily move suggests a binary event of this magnitude could drive a multi-standard-deviation move.
Drug in focus
QURE drug pipeline →AMT-130
▲ Bullish Named in this press release- Impact
- Phase
- Phase 1/2 (pivotal for accelerated approval)
- Time to market
- BLA submission planned for Q3 2026; FDA accelerated approval decision likely 6-10 months after submission (potentially H1 2027)
- Next catalyst
- None dated
What to watchThe BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 2 $22.97entry
- T+1 · 14d ago +3.92%α +3.62% · $23.87
- T+5 · 8d ago −0.78%α −0.86% · $22.79
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
uniQure announced FDA acceptance and Priority Review of its BLA for ifezuntirgene inilparvovec (AMT-130), a gene therapy for Huntington's disease, with a PDUFA target action date of May 1, 2027. The FDA plans an Advisory Committee meeting and the confirmatory Phase III trial is expected to begin screening by end of 2026. If approved, this would be the first disease-modifying treatment for Huntington's disease, a large unmet need with ~75,000 patients in the US, EU, and UK.
Key Facts
- FDA accepted BLA for ifezuntirgene inilparvovec (AMT-130) for Huntington's disease under Accelerated Approval pathway
- Granted Priority Review with PDUFA target action date of May 1, 2027
- FDA tentatively planning an Advisory Committee meeting
- BLA supported by 36-month Phase I/II data vs. propensity score-matched external control from Enroll-HD database
- Confirmatory trial design aligned with FDA: randomized 2:1 vs standard of care, ~200 patients, TFC primary endpoint at 36 months; screening to begin by end of 2026
- First investigational therapy for Huntington's disease to receive Breakthrough Therapy and RMAT designations; also holds Fast Track designation
- Approximately 75,000 people have Huntington's disease in the US, EU, and UK; no approved disease-modifying therapies exist
- Market cap ~$1.8B; normal daily move 3.1%
Financial Impact
First disease-modifying treatment for a large unmet-need population of ~75,000 patients in developed markets; no approved competitors. Approval would transform uniQure's revenue profile from its current hemophilia B gene therapy base.
Risk Factors
- FDA may require additional data from the confirmatory trial before granting full approval; Accelerated Approval is not guaranteed
- AdCom vote could be negative or split, creating uncertainty
- Phase I/II data, while supportive, is from a small non-randomized study with an external control, FDA may view the evidence as insufficient for accelerated approval
- Manufacturing or CMC issues could delay approval or result in a CRL
- If approved, commercial adoption depends on pricing, reimbursement, and the logistical complexity of MRI-guided neurosurgical delivery
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393020 |
Track record
38 reports on QURE
5 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Viewing Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers